Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1888MR)

This product GTTS-WQ1888MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Cervical Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1888MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14242MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ685MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ9393MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ5421MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ4603MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ15507MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ2256MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ9552MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J6M0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW